Peptides (mini proteins) have outstanding potential as new drugs for cancer, pain and many other diseases, but their potential has not been realised so far because peptides tend to be unstable in the body. I have discovered a new class of peptides that are ultra-stable and have very favourable pharmaceutical properties. I will use these peptides to develop a new generation of drugs that are more potent and with fewer side effects than traditional drugs.
Development Of New Anticancer Drugs Using Sortase-mediated Ligation
Funder
National Health and Medical Research Council
Funding Amount
$618,274.00
Summary
There is a great need for new cancer treatments. We are developing cyclic peptides as the next generation of safe and effective cancer drugs. Cyclic peptides, unlike their linear counterparts, display high stability and oral bioavailability, as well as high solubility and negligible immune response. One of the hurdles is the cyclisation process and we aim to develop enzyme-mediated cyclisation as a convenient and cost effective method for cyclic peptide production.
Venoms To Drugs: Translating Venom Peptides Into Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$751,854.00
Summary
Chronic pain is a major global health problem that currently affects over three million Australians. There are few drugs available for treating chronic pain and many have significant side-effects. Several ion channels are critical for conducting pain signals to the brain. Blocking these channels can provide pain relief and, in some cases, protection from brain injury following stroke. We are producing potent and selective blockers of these ion channels for the treatment of chronic pain and strok ....Chronic pain is a major global health problem that currently affects over three million Australians. There are few drugs available for treating chronic pain and many have significant side-effects. Several ion channels are critical for conducting pain signals to the brain. Blocking these channels can provide pain relief and, in some cases, protection from brain injury following stroke. We are producing potent and selective blockers of these ion channels for the treatment of chronic pain and stroke.Read moreRead less